Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options-An Analysis From the Global Germ Cell Cancer Group
Standard
Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options-An Analysis From the Global Germ Cell Cancer Group. / Feldman, Darren R; Lorch, Anja; Kramar, Andrew; Albany, Costantine; Einhorn, Lawrence H; Giannatempo, Patrizia; Necchi, Andrea; Flechon, Aude; Boyle, Helen; Chung, Peter; Huddart, Robert A; Bokemeyer, Carsten; Tryakin, Alexey; Sava, Teodoro; Winquist, Eric William; De Giorgi, Ugo; Aparicio, Jorge; Sweeney, Christopher J; Cohn Cedermark, Gabriella; Beyer, Jörg; Powles, Thomas.
in: J CLIN ONCOL, Jahrgang 34, Nr. 4, 01.02.2016, S. 345-51.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Brain Metastases in Patients With Germ Cell Tumors: Prognostic Factors and Treatment Options-An Analysis From the Global Germ Cell Cancer Group
AU - Feldman, Darren R
AU - Lorch, Anja
AU - Kramar, Andrew
AU - Albany, Costantine
AU - Einhorn, Lawrence H
AU - Giannatempo, Patrizia
AU - Necchi, Andrea
AU - Flechon, Aude
AU - Boyle, Helen
AU - Chung, Peter
AU - Huddart, Robert A
AU - Bokemeyer, Carsten
AU - Tryakin, Alexey
AU - Sava, Teodoro
AU - Winquist, Eric William
AU - De Giorgi, Ugo
AU - Aparicio, Jorge
AU - Sweeney, Christopher J
AU - Cohn Cedermark, Gabriella
AU - Beyer, Jörg
AU - Powles, Thomas
N1 - © 2015 by American Society of Clinical Oncology.
PY - 2016/2/1
Y1 - 2016/2/1
N2 - PURPOSE: To define characteristics, treatment response, and outcomes of men with brain metastases (BM) from germ cell tumors (GCT).PATIENTS AND METHODS: Data from 523 men with BM from GCT were collected retrospectively from 46 centers in 13 countries by using standardized questionnaires. Clinical features were correlated with overall survival (OS) as the primary end point.RESULTS: BM were present at initial diagnosis in 228 men (group A) and at relapse in 295 men (group B). OS at 3 years (3-year OS) was superior in group A versus group B (48% v 27%; P < .001). Multiple BM and the presence of liver or bone metastasis were independent adverse prognostic factors in both groups; primary mediastinal nonseminoma (group A) and elevations of α-fetoprotein of 100 ng/mL or greater or of human chorionic gonadotropin of 5,000 U/L or greater (group B) were additional independent adverse prognostic factors. Depending on these factors, the 3-year OS ranged from 0% to 70% in group A and from 6% to 52% in group B. In group A, 99% of patients received chemotherapy; multimodality treatment or high-dose chemotherapy was not associated with statistically improved survival in multivariable analysis. In group B, only 54% of patients received chemotherapy; multimodality treatment was associated with improved survival compared with single-modality therapy (hazard ratio, 0.51; 95% CI, 0.36 to 0.73; P < .001), as was high-dose compared with conventional-dose chemotherapy (hazard ratio, 0.41; 95% CI, 0.24 to 0.70; P = .001).CONCLUSION: Men with BM from GCT have poor OS, particularly if additional risk factors are present. High-dose chemotherapy and multimodality treatment seemed to improve survival probabilities in men with BM at relapse.
AB - PURPOSE: To define characteristics, treatment response, and outcomes of men with brain metastases (BM) from germ cell tumors (GCT).PATIENTS AND METHODS: Data from 523 men with BM from GCT were collected retrospectively from 46 centers in 13 countries by using standardized questionnaires. Clinical features were correlated with overall survival (OS) as the primary end point.RESULTS: BM were present at initial diagnosis in 228 men (group A) and at relapse in 295 men (group B). OS at 3 years (3-year OS) was superior in group A versus group B (48% v 27%; P < .001). Multiple BM and the presence of liver or bone metastasis were independent adverse prognostic factors in both groups; primary mediastinal nonseminoma (group A) and elevations of α-fetoprotein of 100 ng/mL or greater or of human chorionic gonadotropin of 5,000 U/L or greater (group B) were additional independent adverse prognostic factors. Depending on these factors, the 3-year OS ranged from 0% to 70% in group A and from 6% to 52% in group B. In group A, 99% of patients received chemotherapy; multimodality treatment or high-dose chemotherapy was not associated with statistically improved survival in multivariable analysis. In group B, only 54% of patients received chemotherapy; multimodality treatment was associated with improved survival compared with single-modality therapy (hazard ratio, 0.51; 95% CI, 0.36 to 0.73; P < .001), as was high-dose compared with conventional-dose chemotherapy (hazard ratio, 0.41; 95% CI, 0.24 to 0.70; P = .001).CONCLUSION: Men with BM from GCT have poor OS, particularly if additional risk factors are present. High-dose chemotherapy and multimodality treatment seemed to improve survival probabilities in men with BM at relapse.
U2 - 10.1200/JCO.2015.62.7000
DO - 10.1200/JCO.2015.62.7000
M3 - SCORING: Journal article
C2 - 26460295
VL - 34
SP - 345
EP - 351
JO - J CLIN ONCOL
JF - J CLIN ONCOL
SN - 0732-183X
IS - 4
ER -